Common-Size Income Statement
Paying user area
Try for free
Micron Technology Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Micron Technology Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Based on: 10-K (reporting date: 2024-08-29), 10-K (reporting date: 2023-08-31), 10-K (reporting date: 2022-09-01), 10-K (reporting date: 2021-09-02), 10-K (reporting date: 2020-09-03), 10-K (reporting date: 2019-08-29).
- Revenue and Cost of Goods Sold
- Revenue remained constant at 100% across all periods, serving as the baseline for analysis. Cost of goods sold (COGS) exhibited significant volatility, starting at -54.28% and peaking dramatically at -109.11% in the period ending August 31, 2023, indicating a substantial increase in production or procurement costs relative to revenue. This peak was followed by a decline to -77.65% in the subsequent period, suggesting some mitigation in cost pressures yet remaining elevated compared to earlier years.
- Gross Margin Trends
- Gross margin as a percentage of revenue showed a downward trend from 45.72% in 2019 to a low of -9.11% in 2023, reflecting the extreme cost increases in that year. The margin partially recovered to 22.35% in 2024 but remained well below historical levels, highlighting ongoing challenges in maintaining profitability at the gross level.
- Operating Expenses
- Research and development costs fluctuated, peaking at -20.04% in 2023, which was nearly double the 2019 level of -10.43%, suggesting increased investment or escalated expenses in innovation during the challenging period. Selling, general, and administrative expenses rose modestly during the downturn, reaching -5.92% in 2023 before declining slightly to -4.5%. Restructuring and asset impairments were generally small but notable in 2021 and 2023, indicating occasional non-recurring costs. Other operating income and expenses varied without a clear pattern but showed a positive spike to 1% in 2024.
- Non-Operating Items
- Interest income and expense both increased over time, with interest income rising to 3.01% in 2023 and falling slightly thereafter. Interest expense showed a peak at -2.5% in 2023 but declined slightly in the latest period. Gains and losses on investments and on debt repurchases were minor and volatile without a consistent trend. The presence of a patent cross-license agreement gain in 2024 (0.8%) and a decline in losses on property disposition suggested some favorable non-operating influences in the latest period.
- Income and Profitability
- Operating income experienced a marked decline, from a strong positive 31.51% in 2019 to a substantial loss of -36.97% in 2023, reflecting the gross margin collapse and elevated operating costs. By 2024, operating income improved but remained low at 5.19%. Income before tax and net income mirrored this pattern, showing sharp declines in 2023 followed by modest recoveries. Net income attributable to the company dropped from 26.97% to -37.54% in 2023, followed by a recovery to 3.1% in 2024, indicating significant volatility likely driven by cost pressures and market conditions.
- Tax and Equity Income
- Income tax provision remained relatively stable and low as a percentage of revenue, ranging between -1.14% and -2.96%. Equity in net income of equity method investees was minimal across all periods, showing no material impact on overall profitability.
- Summary Insights
- The data reveals a period of considerable financial stress around 2023, characterized by a severe increase in cost of goods sold and operating expenses, resulting in negative gross margins and net losses. The subsequent partial recovery in 2024 suggests some stabilization efforts. Elevated research and development expenses during the downturn indicate strategic investment possibly aimed at long-term growth. Non-operating gains in 2024 contributed somewhat to improved profitability. Overall, the financial performance exhibits high cyclicality with significant susceptibility to cost fluctuations and operational challenges.